FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:545-548 February 19, 1998 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Ware, J. H. Related Article by The GUSTO Investigators Related Article by The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators PubMed Citation

To the Editor: The investigators in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) trial (Oct. 16 issue)¹ make an important comparison between reteplase and alteplase, but their investigation has a serious flaw — namely, the lack of blinding. This may have led to serious biases. Might patients have had more anxiety (and more tachycardia and catecholamine release) if they knew they were receiving the experimental treatment instead of the standard treatment? Might a doctor subconsciously treat a patient differently if chest pain continued for half an hour after the completion of treatment (with reteplase) than . . . [Full Text of this Article]

References

This article has been cited by other articles:

• WALLEY, T., DUNDAR, Y., HILL, R., DICKSON, R. (2003). Superiority and equivalence in thrombolytic drugs: an interpretation. QJM 96: 155-160 [Full Text]